Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Reduced dose post-transplant cytoxan (Intermediate -Dose) in combination with abatacept after matched unrelated donor transplant for high -risk hematological malignancy may reduce treatment related mortality and risk of relapse.

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMegan SmithANAndrew D. Nguyen

Discussion

Loading...

Member takes

Overview

Retrospective review shows reduced treatment-related mortality and relapse in high-risk hematological malignancy patients with abatacept and tacrolimus.

Key Points

  • Evaluate the safety and efficacy of reduced-dose post-transplant cyclophosphamide with abatacept and tacrolimus.
  • Retrospective review of patients receiving >8/8 matched unrelated donor PBSCT with reduced dose PTCy, abatacept, and tacrolimus.
  • Cyclophosphamide dosed at 25 mg/kg; abatacept dosed at 10 mg/kg with protocol amendment for additional dose.
  • Patients' conditioning regimens varied with reduced and full intensity chemotherapy.
  • Cumulative incidence of relapse was 21.3% at one year and treatment-related mortality was 12.3% at one year.
  • Median time to neutrophil recovery was 12.6 days and platelet recovery was 20.6 days.
  • Acute graft-versus-host disease occurred in 38.9% of patients, all grade 1/2.

Cite This Study

Smith et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d886https://doi.org/10.1182/blood-2025-4196
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Reduced Dose of Post-transplant Cyclophosphamide with Tacrolimus for the Prevention of Graft-versus-Host Disease in HLA-Matched Donor Peripheral Blood Stem Cell Transplants: A Prospective Pilot Study2024 · 2 citations
  2. 2Reduced Dose of Post-Transplant Cyclophosphamide with Tacrolimus for the Prevention of Graft-versus-Host Disease in HLA-Matched Donor Peripheral Blood Stem Cell Transplants: A Prospective Pilot Study2024 · 19 citations
  3. 3Abatacept in combination with post-transplant cyclophosphamide and tacrolimus may improve survival and non-relapse mortality without increasing relapse risk after allogeneic stem cell transplantation2025
  4. 4ABC: Highly active and entirely calcineurin and m-TOR inhibitor-free gvhd prevention regimen2025
  5. 5Exploring the efficacy and safety of low-dose ATG combined with fractionated low-dose ptcy in preventing gvhd after allogeneic hematopoietic stem cell transplantation2025 · 1 citations